Risk for leukemia in infants without down syndrome who have transient myeloproliferative disorder

Journal of Pediatrics

Volumn 148, Issue 5, 2006, Pages 687-689

  Cushing, Thomas ^a,b,c,d   Clericuzio, Carol L ^a,b,c,d   Wilson, Carla S ^a,b,c,d   Taub, Jeffrey W ^a,b,c,d   Ge, Yubin ^a,b,c,d   Reichard, Kaaren K ^a,b,c,d   Winter, Stuart S ^a,b,c,d  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^c KARMANOS CANCER INSTITUTE   (United States)

^d CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR GATA 1;

ACUTE MEGAKARYOCYTIC LEUKEMIA; ARTICLE; BLAST CELL; CASE REPORT; CHROMOSOME ANALYSIS; DOWN SYNDROME; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; HUMAN; LABORATORY TEST; MALE; MOSAICISM; MYELOPROLIFERATIVE DISORDER; NEWBORN; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RISK FACTOR;

BONE MARROW CELLS; DOWN SYNDROME; GATA1 TRANSCRIPTION FACTOR; HUMANS; INFANT, NEWBORN; LEUKEMIA, MEGAKARYOCYTIC, ACUTE; MALE; MOSAICISM; MUTATION; MYELOPROLIFERATIVE DISORDERS; RISK ASSESSMENT;

EID: 33646842013     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpeds.2005.12.031     Document Type: Article

References (13)

1. Ge Y., Jensen T.L., Stout M.L., Flatley R.M., Grohar P.J., Ravindranath Y., et al. The role of cytidine deaminase and GATA1 mutations in the increased cytosine arabinoside sensitivity of Down syndrome myeloblasts and leukemia cell lines. Cancer Res 64 (2004) 728-735
2. Karandikar N.J., Aquino D.B., McKenna R.W., and Kroft S.H. Transient myeloproliferative disorder and acute myeloid leukemia in Down syndrome. an immunophenotypic analysis. Am J Clin Pathol 116 (2001) 204-210
3. Wong K.Y., Jones M.M., Srivastava A.K., and Gruppo R.A. Transient myeloproliferative disorder and acute nonlymphoblastic leukemia in Down syndrome. J Pediatr 112 (1988) 18-22
4. Massey G.V. Transient leukemia in newborns with Down syndrome. Pediatr Blood Cancer 44 (2005) 29-32
5. Taub J.W., Mundschau G., Ge Y., Poulik J.M., Qureshi F., Jensen T., et al. Prenatal origin of GATA1 mutations may be an initiating step in the development of megakaryocytic leukemia in Down syndrome. Blood 104 (2004) 1588-1589
6. Crispino J.D. GATA1 mutations in Down syndrome. implications for biology and diagnosis of children with transient myeloproliferative disorder and acute megakaryoblastic leukemia. Pediatr Blood Cancer 44 (2005) 40-44
7. Polski J.M., Galambos C., Gale G.B., Dunphy C.H., Evans H.L., and Batanian J.R. Acute megakaryoblastic leukemia after transient myeloproliferative disorder with clonal karyotype evolution in a phenotypically normal neonate. J Pediatr Hematol Oncol 24 (2002) 50-54
8. Homans A.C., Verissimo A.M., and Vlacha V. Transient abnormal myelopoiesis of infancy associated with trisomy 21. Am J Pediatr Hematol Oncol 15 (1993) 392-399
9. Isaacs Jr. H. Fetal and neonatal leukemia. J Pediatr Hematol Oncol 25 (2003) 348-361
10. Gurbuxani S., Vyas P., and Crispino J.D. Recent insights into the mechanisms of myeloid leukemogenesis in Down syndrome. Blood 103 (2004) 399-406
11. Magalhaes I.Q., Splendore A., Emerenciano M., Cordoba M.S., Cordoba J.C., Allemand P.A., et al. Transient neonatal myeloproliferative disorder without Down syndrome and detection of GATA1 mutation. J Pediatr Hematol Oncol 27 (2005) 50-52
12. Lange B.J., Kobrinsky N., Barnard D.R., Arthur D.C., Buckley J.D., Howells W.B., et al. Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome. Children's Cancer Group studies 2861 and 2891. Blood 91 (1998) 608-615
13. Athale U.H., Razzouk B.I., Raimondi S.C., Tong X., Behm F.G., Head D.R., et al. Biology and outcome of childhood acute megakaryoblastic leukemia. a single institution's experience. Blood 97 (2001) 3727-3732